Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.43 |
| ▸ | SLC2A3 | P11169 | 3/20 | 0.43 |
| ▸ | SLC2A2 | P11168 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838566 | 0.93 | SLC2A1 (0.46) | GCKKCNH2SLC2A1SLC2A3SLC2A2 | |
| SCHEMBL839168 | 0.88 | GCK (0.47) | GCKKCNH2SLC2A1SLC2A3SLC2A2 | |
| SCHEMBL839952 | 0.86 | MAPK14 (0.47) | GCKKCNH2MAPTMAPK14TP53 | |
| SCHEMBL839578 | 0.82 | SLC2A1 (0.56) | GCKKCNH2SLC2A1SLC2A3SLC2A2 | |
| SCHEMBL878648 | 0.80 | KDM4E (0.43) | MAPTXDHMAPK14TP53KDM4E | |
| SCHEMBL838945 | 0.80 | MAPK14 (0.41) | MAPTMAPK14TP53KDM4EMEN1 | |
| SCHEMBL838279 | 0.80 | GCK (0.44) | GCKKCNH2SLC2A1SLC2A3SLC2A2 | |
| SCHEMBL839711 | 0.80 | SLC2A1 (0.47) | SLC2A1SLC2A3SLC2A2MAPTXDH | |
| SCHEMBL839999 | 0.77 | SLC2A1 (0.46) | GCKKCNH2SLC2A1SLC2A3SLC2A2 | |
| SCHEMBL25342469 | 0.75 | SLC2A1 (0.43) | GCKKCNH2SLC2A1SLC2A3SLC2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8071608-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071608-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071608-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| CN-102171213-A | Pyrazolo [3, 4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity | ASTRAZENECA AB | 2011-08-31 | — | — | CN | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010116176-A1 | PYRAZOLO [4, 5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010116176-A1 | PYRAZOLO [4, 5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | GCK 1/4885KCNH2 1438/4885SLC2A1 14/4885 |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | GCK, GCKR, GALK1 | GCK 1/4885KCNH2 437/4885SLC2A1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.